BackgroundTo investigate the impact of preoperative glycosylated hemoglobin A1C (HbA1c) among patients following curative‐intent resection of nonfunctional gastroentropancreatic neuroendocrine tumors (GEP‐NETs).MethodsPatients who underwent curative‐intent resection for GEP‐NETs from 2000 to 2020 were identified from the US Neuroendocrine Tumor Study Group (US‐NETSG). Preoperative blood HbA1c levels were defined as high HbA1c (≥ 6.5%) versus low HbA1c group (< 6.5%). Impact of HbA1c level on postoperative short‐term and long‐term overall (OS) were investigated.ResultsA total of 130 patients with HbA1c < 6.5% and 60 patients with HbA1c ≥ 6.5% were included. Patients with HbA1c ≥ 6.5% had higher proportion of comorbidities, such as hypertension, obesity, anemia, and lower preoperative albumin levels versus patients with HbA1c < 6.5% (all p < 0.05). In addition, high level of preoperative HbA1c was associated with increased incidence of wound and infectious complications, as well as decreased long‐term OS (median OS: high Hb1Ac 89.8 months vs. low Hb1Ac not reached, HR 3.487, p = 0.004) among patients with nonfunctional GEP‐NETs, as well as among the subset of pancreatic NET patients (median OS: high Hb1Ac 74.3 months vs. low Hb1Ac not reached, p = 0.004), and patients with normal fasting blood glucose (< 140 mg/dL) (median OS: high Hb1Ac 75.4 months vs. low Hb1Ac not reached, p = 0.001).ConclusionsHb1Ac might have value as a screening tool to identify high‐risk patients following surgical resection of nonfunctional GEP‐NETs for consideration of more strict postoperative surveillance and treatment of elevated Hb1Ac level.